Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?

A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer

(2021) Fangzhen Lin et al.   Frontiers in Oncology

“The use of bisphosphonates to treat skeletal complications in solid tumours”

(2021) S. D’Oronzo- et al.   BONE

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?

(2021) Vicenç Ruiz de Porras et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors

(2021) Gerald S. Falchook et al.   INVESTIGATIONAL NEW DRUGS

Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin

(2021) Yuan Cheng et al.   Molecular Cancer

Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives

(2021) Vicenç Ruiz de Porras et al.   CANCER LETTERS

Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting

(2021) Maosen Xu et al.   CELL PROLIFERATION

Prostate cancer

(2021) Shahneen Sandhu et al.   LANCET

The treatment landscape of metastatic prostate cancer

(2021) Yasutaka Yamada et al.   CANCER LETTERS

The role of regulatory T cells in liver transplantation

(2021) Zahra Beyzaei et al.   TRANSPLANT IMMUNOLOGY

Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment

(2021) Wan-Lun Yan et al.   Journal for ImmunoTherapy of Cancer

Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers

(2021) Brian W. Labadie et al.   Cancers

CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis

(2020) Hui Yang et al.   Molecular Cancer

Human chimeric antigen receptor macrophages for cancer immunotherapy

(2020) Michael Klichinsky et al.   NATURE BIOTECHNOLOGY

Olaparib for Metastatic Castration-Resistant Prostate Cancer

(2020) Johann de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating β-catenin/STAT3 signaling

(2020) Renlun Huang et al.   Cell Death & Disease

Multicenter Phase 1 Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer

(2020) Christos E. Kyriakopoulos et al.   CLINICAL CANCER RESEARCH

CXCR2 signaling promotes secretory cancer‐associated fibroblasts in pancreatic ductal adenocarcinoma

(2020) Mohammad Awaji et al.   FASEB JOURNAL

The Role of Cancer-Associated Fibroblasts in Prostate Cancer Tumorigenesis

(2020) Francesco Bonollo et al.   Cancers

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

(2020) Karen A. Autio et al.   CLINICAL CANCER RESEARCH

Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion

(2020) Bianca Cioni et al.   Nature Communications

Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1+ TAMs

(2019) Betul Gok Yavuz et al.   Scientific Reports

Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer

(2019) Congcong Wu et al.   CLINICAL & EXPERIMENTAL METASTASIS

Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy

(2019) Sumanta Pal et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Genomic correlates of clinical outcome in advanced prostate cancer

(2019) Wassim Abida et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

(2019) William D Tap et al.   LANCET

CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy

(2019) Amira A. Barkal et al.   NATURE

Diversity, Mechanisms, and Significance of Macrophage Plasticity

(2019) Massimo Locati et al.   Annual Review of Pathology-Mechanisms of Disease

CXCR2 expression on granulocyte and macrophage progenitors under tumor conditions contributes to mo-MDSC generation via SAP18/ERK/STAT3

(2019) Xiaoqing Han et al.   Cell Death & Disease

Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer

(2019) Diletta Di Mitri et al.   Cell Reports

The Mononuclear Phagocytic System. Generation of Diversity

(2019) Siamon Gordon et al.   Frontiers in Immunology

Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization

(2019) Nai-Yun Sun et al.   Cancers

GM-CSF in inflammation

(2019) John A. Hamilton   JOURNAL OF EXPERIMENTAL MEDICINE

Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial

(2019) Paul G Corn et al.   LANCET ONCOLOGY

Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer

(2019) Douglas G. McNeel et al.   JOURNAL OF CLINICAL ONCOLOGY

Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials

(2018) Yongquan Wang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Macrophage plasticity, polarization, and function in health and disease

(2018) Abbas Shapouri-Moghaddam et al.   JOURNAL OF CELLULAR PHYSIOLOGY

[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

(2018) Michael S Hofman et al.   LANCET ONCOLOGY

Clinical implications of PTEN loss in prostate cancer

(2018) Tamara Jamaspishvili et al.   Nature Reviews Urology

Metastatic Prostate Cancer

(2018) Oliver Sartor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of effectiveness of granulocyte-macrophage colony-stimulating factor therapy to cancer patients after chemotherapy: a meta-analysis

(2018) Wen-Liang Yu et al.   Oncotarget

Chimeric antigen receptors that trigger phagocytosis

(2018) Meghan A Morrissey et al.   eLife

Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?

(2018) Mario Rotondi et al.   Frontiers in Endocrinology

Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial

(2018) Michael J. Seider et al.   ANNALS OF NUCLEAR MEDICINE

Tumor-associated macrophages secrete CCL2 and induce the invasive phenotype of human breast epithelial cells through upregulation of ERO1-α and MMP-9

(2018) Seungeun Lee et al.   CANCER LETTERS

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients

(2018) Emilia Lubowicka et al.   Biomed Research International

High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy

(2018) Matthew M. Gubin et al.   CELL

Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy

(2018) Mark Ayers et al.   CLINICAL CANCER RESEARCH

Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations

(2018) Emmanuel S. Antonarakis et al.   EUROPEAN UROLOGY

M2 macrophages and regulatory T cells in lethal prostate cancer

(2018) Ann Erlandsson et al.   PROSTATE

CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer

(2018) Shenglan Gu et al.   Journal of Immunology Research

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

(2018) Wassim Abida et al.   JAMA Oncology

High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors

(2018) Saman Maleki Vareki   Journal for ImmunoTherapy of Cancer

Recent progress in GM-CSF-based cancer immunotherapy

(2017) Wan-Lun Yan et al.   Immunotherapy

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases

(2017) Andrew L. Himelstein et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Shp1 function in myeloid cells

(2017) Clare L. Abram et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies

(2017) Zoila Lopez-Bujanda et al.   JOURNAL OF LEUKOCYTE BIOLOGY

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

(2017) Karim Fizazi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model

(2017) Hua Tao et al.   ONCOLOGY RESEARCH

COX2/mPGES1/PGE2pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells

(2017) Victor Prima et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging

(2017) Michael F. Cuccarese et al.   Nature Communications

CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis

(2017) Ran Liu et al.   Oncotarget

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

(2016) Colin W. Steele et al.   CANCER CELL

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

(2016) Kipp Weiskopf et al.   JOURNAL OF CLINICAL INVESTIGATION

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer

(2016) Cora Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

(2016) Nicholas D James et al.   LANCET

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

(2016) Padmanee Sharma et al.   LANCET ONCOLOGY

Increased Expression of CSF-1 Associates With Poor Prognosis of Patients With Gastric Cancer Undergoing Gastrectomy

(2016) Hao Liu et al.   MEDICINE

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

(2016) Hong Jiang et al.   NATURE MEDICINE

Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials

(2016) Heleen H. Van Acker et al.   PHARMACOLOGY & THERAPEUTICS

Cd47-Sirpα interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells

(2016) Zhen Bian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial

(2016) Andrew J. Armstrong et al.   PROSTATE

Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment

(2016) Manuela Liguori et al.   Oncotarget

High expression of C-C chemokine receptor 2 associates with poor overall survival in gastric cancer patients after surgical resection

(2016) Ruochen Li et al.   Oncotarget

Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22–CCR4 axis

(2016) Aerken Maolake et al.   Oncotarget

Targeting the CCL2-CCR2 signaling axis in cancer metastasis

(2016) Su Yin Lim et al.   Oncotarget

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both

(2016) Nicholas D. James et al.   JAMA Oncology

CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer

(2016) Hui Zhao et al.   Scientific Reports

Monocyte and Macrophage Plasticity in Tissue Repair and Regeneration

(2015) Amitava Das et al.   AMERICAN JOURNAL OF PATHOLOGY

Macrophages and Therapeutic Resistance in Cancer

(2015) Brian Ruffell et al.   CANCER CELL

Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma

(2015) Zhenyu Xiao et al.   CANCER LETTERS

CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy

(2015) J. Escamilla et al.   CANCER RESEARCH

Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity

(2015) Alan Serrels et al.   CELL

GM-CSF: An immune modulatory cytokine that can suppress autoimmunity

(2015) Palash Bhattacharya et al.   CYTOKINE

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

(2015) Christopher J. Sweeney et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells

(2015) Huimin Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma

(2015) WENXUE HU et al.   Oncology Letters

Secreted Factors from Colorectal and Prostate Cancer Cells Skew the Immune Response in Opposite Directions

(2015) Marie Lundholm et al.   Scientific Reports

Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma

(2015) Shin Foong Ngiow et al.   OncoImmunology

Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment

(2015) Anders Olsson et al.   Journal for ImmunoTherapy of Cancer

Prostate cancer-derived CCN3 induces M2 macrophage infiltration and contributes to angiogenesis in prostate cancer microenvironment

(2015) Po-Chun Chen et al.   Oncotarget

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

(2014) M D’Incalci et al.   BRITISH JOURNAL OF CANCER

Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer

(2014) Manja Idorn et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

(2014) Y. Zhu et al.   CANCER RESEARCH

Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines

(2014) Peter J. Murray et al.   IMMUNITY

Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)

(2014) Matthew R. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study

(2014) Igor Tsaur et al.   Cancer Research and Treatment

Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models

(2014) L. Shen et al.   Cancer Immunology Research

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

(2013) Giovanni Germano et al.   CANCER CELL

Mechanisms of action of tasquinimod on the tumour microenvironment

(2013) E. Raymond et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer

(2013) J. Xu et al.   CANCER RESEARCH

Induction of Siglec-G by RNA Viruses Inhibits the Innate Immune Response by Promoting RIG-I Degradation

(2013) Weilin Chen et al.   CELL

Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

(2013) A. J. Armstrong et al.   CLINICAL CANCER RESEARCH

M1 and M2 Macrophages: Oracles of Health and Disease

(2013) Charles Mills   CRITICAL REVIEWS IN IMMUNOLOGY

Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation

(2013) Kouji Izumi et al.   EMBO Molecular Medicine

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

(2013) C. Parker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression

(2013) G Comito et al.   ONCOGENE

Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor

(2013) C. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The tumor microenvironment is a dominant force in multidrug resistance

(2012) Ana Luísa Correia et al.   DRUG RESISTANCE UPDATES

Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis

(2012) Bradley J. Monk et al.   EUROPEAN JOURNAL OF CANCER

Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death

(2012) Magali Castells et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Macrophage Proliferation Is Regulated through CSF-1 Receptor Tyrosines 544, 559, and 807

(2012) Wenfeng Yu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis

(2012) Thomas Jamieson et al.   JOURNAL OF CLINICAL INVESTIGATION

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

(2012) Charles J. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatocellular carcinoma and macrophage interaction induced tumor immunosuppressionviaTreg requires TLR4 signaling

(2012) Jing Yang   WORLD JOURNAL OF GASTROENTEROLOGY

The Outgrowth of Micrometastases Is Enabled by the Formation of Filopodium-like Protrusions

(2012) Tsukasa Shibue et al.   Cancer Discovery

CSF1 Expression in Nongynecological Leiomyosarcoma Is Associated with Increased Tumor Angiogenesis

(2011) Iñigo Espinosa et al.   AMERICAN JOURNAL OF PATHOLOGY

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer

(2011) M. D. Michaelson et al.   ANNALS OF ONCOLOGY

Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti-CTLA-4 Therapy

(2011) R. Waitz et al.   CANCER RESEARCH

PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine

(2011) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Phosphorylation of CSF-1R Y721 mediates its association with PI3K to regulate macrophage motility and enhancement of tumor cell invasion

(2011) N. G. Sampaio et al.   JOURNAL OF CELL SCIENCE

Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

(2011) Roberto Pili et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour macrophages as potential targets of bisphosphonates

(2011) Thea L Rogers et al.   Journal of Translational Medicine

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment

(2011) J. B. Stokes et al.   MOLECULAR CANCER THERAPEUTICS

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer

(2010) Norio Nonomura et al.   BJU INTERNATIONAL

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK–RhoA signaling pathway

(2009) S Senapati et al.   ONCOGENE

Anti-CTLA-4 therapy results in higher CD4+ICOShiT cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

(2009) Hong Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

(2008) Dominik R. Berthold et al.   JOURNAL OF CLINICAL ONCOLOGY